VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 410 filers reported holding VALEANT PHARMACEUTICALS INTL in Q4 2013. The put-call ratio across all filers is 0.62 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2015 | $1,067,000 | -85.2% | 10,493 | -74.0% | 0.04% | -88.1% |
| Q3 2015 | $7,188,000 | -33.4% | 40,293 | -17.0% | 0.29% | -15.0% |
| Q2 2015 | $10,788,000 | +338.9% | 48,562 | +292.4% | 0.35% | +311.9% |
| Q1 2015 | $2,458,000 | +84.3% | 12,377 | +32.8% | 0.08% | +75.0% |
| Q4 2014 | $1,334,000 | +6.5% | 9,321 | -2.4% | 0.05% | +6.7% |
| Q3 2014 | $1,253,000 | +24.4% | 9,552 | +19.6% | 0.04% | +104.5% |
| Q2 2014 | $1,007,000 | +3.1% | 7,987 | +7.7% | 0.02% | -12.0% |
| Q1 2014 | $977,000 | -23.3% | 7,413 | -31.7% | 0.02% | -53.7% |
| Q4 2013 | $1,274,000 | +14.2% | 10,856 | +1.5% | 0.05% | +8.0% |
| Q3 2013 | $1,116,000 | -14.4% | 10,698 | -29.3% | 0.05% | -27.5% |
| Q2 2013 | $1,303,000 | +107.5% | 15,134 | +7.9% | 0.07% | +86.5% |
| Q2 2012 | $628,000 | -5.6% | 14,024 | +13.3% | 0.04% | +2.8% |
| Q1 2012 | $665,000 | -5.5% | 12,377 | -17.9% | 0.04% | -41.9% |
| Q4 2011 | $704,000 | +38.0% | 15,082 | +9.9% | 0.06% | +29.2% |
| Q3 2011 | $510,000 | – | 13,729 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 6,050,442 | $763,082,000 | 30.78% |
| LeVasseur Capital Partners LLC | 190,404 | $24,014,000 | 29.50% |
| FARLEY CAPITAL L.P. | 333,081 | $42,008,000 | 27.09% |
| Ruane, Cunniff & Goldfarb | 34,298,384 | $4,325,712,000 | 23.07% |
| ValueAct Holdings | 18,923,877 | $2,386,679,000 | 17.64% |
| Tesuji Partners | 1,368,040 | $172,537,000 | 17.22% |
| Brahman Capital Corp. | 3,902,877 | $492,231,000 | 13.63% |
| Arrow Capital Management, LLC | 197,500 | $24,909,000 | 13.60% |
| Hound Partners | 2,851,175 | $359,590,000 | 13.45% |
| Ratan Capital Management LP | 731,960 | $92,315,000 | 13.09% |